FINNENCE ▪ THE WIRE FILE
THE WIRE · № 60591
SEC Filing■ Mixed
NKE filed 8-K on 2026-10-01
KINDSEC Filing
DIRECTION■ Mixed
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN2026-10-01 00:00 UTC
LAST UPDATE2026-10-01 00:00 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
An 8-K with earnings plus exit/disposal costs signals restructuring charges alongside results, muddying the read.
Nike results paired with restructuring costs cloud outlook
CATALYST TO WATCH
Management guidance on cost savings
MAIN RISK
Charges could signal deeper demand weakness
FULL DISPATCH
NKE (CIK 0000320187) filed a 8-K on 2026-10-01. 8-K items: item 2.02 (results of operations (earnings)) item 2.05 (costs associated with exit/disposal) item 9.01.
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
SUBJECTNike · NKE
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→INFERENCEfilings generate company commentary
New Phase 3 trial: A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA Nephropathy — Novartis2026-09-30 12:00 UTC
New Phase 3 trial: A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA Nephropathy — Novartis2026-09-30 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease — Boehringer Ingelheim2026-09-30 12:00 UTC
New Phase 3 trial: ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease — Boehringer Ingelheim2026-09-30 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight — Boehringer Ingelheim2026-09-30 12:00 UTC
New Phase 3 trial: SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight — Boehringer Ingelheim2026-09-30 12:00 UTC
→INFERENCEfilings generate company commentary
Phase 3 results posted: Study of PK and Safety of the LicartTM Topical System in Pediatric and Adult Participants With Minor Soft Tissue Injury — IBSA Institut Biochimique SA2026-09-30 12:00 UTC
Phase 3 results posted: Study of PK and Safety of the LicartTM Topical System in Pediatric and Adult Participants With Minor Soft Tissue Injury — IBSA Institut Biochimique SA2026-09-30 12:00 UTC
→INFERENCEfilings generate company commentary
Phase 3 results posted: Study Comparing Estradiol Vaginal Inserts 4mcg To IMVEXXY ® (Estradiol Vaginal Inerts 4 mcg) In The Treatment Of Dyspareunia in Women With Vulvur and Vaginal Atrophy — Teva Pharmaceuticals USA2026-09-30 12:00 UTC
Phase 3 results posted: Study Comparing Estradiol Vaginal Inserts 4mcg To IMVEXXY ® (Estradiol Vaginal Inerts 4 mcg) In The Treatment Of Dyspareunia in Women With Vulvur and Vaginal Atrophy — Teva Pharmaceuticals USA2026-09-30 12:00 UTC
→INFERENCEfilings generate company commentary
Phase 3 results posted: A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases — Takeda2026-09-30 12:00 UTC
Phase 3 results posted: A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases — Takeda2026-09-30 12:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.